Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Charles Lance Cowey"'
Autor:
James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul D. Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey Weber
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::434061b974def7d4b67a0e16b85e1b6e
https://doi.org/10.1158/1078-0432.ccr-22-3145
https://doi.org/10.1158/1078-0432.ccr-22-3145
Autor:
Jeffrey Weber, Paolo A. Ascierto, Sonia Dolfi, Hao Tang, Margarita Askelson, Maurice Lobo, Corey Ritchings, Paola Queirolo, Nikhil I. Khushalani, Paul D. Nathan, Michael Millward, Leslie A. Fecher, Andrew G. Hill, Victoria Atkinson, Petr Arenberger, Luis de la Cruz-Merino, Jose Lutzky, Mark R. Middleton, Anna Maria Di Giacomo, Marcus O. Butler, Ivan Marquez-Rodas, Vanna Chiarion-Sileni, Jean-Jacques Grob, Michael Schenker, Charles Lance Cowey, Stéphane Dalle, Ana M. Arance Fernandez, Helen Gogas, Mario Mandalá, Michele Del Vecchio, James Larkin
DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52cb1057ddae601989ec0e00460b71a9
https://doi.org/10.1158/1078-0432.22787545.v1
https://doi.org/10.1158/1078-0432.22787545.v1
Autor:
Jeffrey Weber, Paolo A. Ascierto, Sonia Dolfi, Hao Tang, Margarita Askelson, Maurice Lobo, Corey Ritchings, Paola Queirolo, Nikhil I. Khushalani, Paul D. Nathan, Michael Millward, Leslie A. Fecher, Andrew G. Hill, Victoria Atkinson, Petr Arenberger, Luis de la Cruz-Merino, Jose Lutzky, Mark R. Middleton, Anna Maria Di Giacomo, Marcus O. Butler, Ivan Marquez-Rodas, Vanna Chiarion-Sileni, Jean-Jacques Grob, Michael Schenker, Charles Lance Cowey, Stéphane Dalle, Ana M. Arance Fernandez, Helen Gogas, Mario Mandalá, Michele Del Vecchio, James Larkin
Purpose:In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30007277e80b61bdf1c2ca6cbcc13787
https://doi.org/10.1158/1078-0432.c.6637744.v1
https://doi.org/10.1158/1078-0432.c.6637744.v1
Autor:
Thao T Vo, Janet L Espirito, Marley Boyd, Burak Gumuscu, Diana Chirovsky, Nicholas J Robert, Ramona F Swaby, Wei Zhou, Charles Lance Cowey
Publikováno v:
Future oncology (London, England). 18(17)
Aim: Real-world treatment patterns and clinical outcomes in advanced cutaneous squamous cell carcinoma were evaluated. Methods: Adults receiving their first systemic therapy for unresectable, locally advanced or recurrent/metastatic cutaneous squamou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e143f10aa73ee1dc0637777b8f5365b5
https://pubmed.ncbi.nlm.nih.gov/35240857
https://pubmed.ncbi.nlm.nih.gov/35240857
Autor:
Charles Lance Cowey, Emilie Scherrer, April Beeks, Clemens Krepler, Marley Boyd, Kathleen M. Aguilar
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 7863-7878 (2020)
Cancer Medicine
Cancer Medicine
Introduction Anti‐PD‐1 monotherapies (aPD‐1) and BRAF/MEK inhibitors (BRAF/MEKi) changed the BRAF‐mutant advanced melanoma treatment landscape. This study aimed to improve the understanding of real‐world treatment patterns and optimal treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96fc6bc46c16e1f918585ef9a89a846d
https://doaj.org/article/ee976dd75d584d12914c8df2bc5510e8
https://doaj.org/article/ee976dd75d584d12914c8df2bc5510e8
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9955a26a9fcdf4eb562da49b8669e6f
https://doi.org/10.1016/j.jaad.2022.06.074
https://doi.org/10.1016/j.jaad.2022.06.074
Autor:
F. Stephen Hodi, Vanna Chiarion -Sileni, Karl D. Lewis, Jean-Jacques Grob, Piotr Rutkowski, Christopher D. Lao, Charles Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Paola Queirolo, Michael Smylie, Marcus O. Butler, Andrew Graham Hill, Ivan Marquez-Rodas, John B. A. G. Haanen, Piyush Durani, Peter Wang, Jedd D. Wolchok, James Larkin
Publikováno v:
Journal of Clinical Oncology. 40:9522-9522
9522 Background: Durable clinical benefit has been achieved with nivolumab (NIVO) + ipilimumab (IPI), including an overall survival (OS) of 49% and a melanoma-specific survival (MSS) of 56%, with median MSS not reached (NR) at 6.5-y minimum follow-up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::585c9988c4aa344770ccb0ccc1dac7b2
https://doi.org/10.1200/jco.2022.40.16_suppl.9522
https://doi.org/10.1200/jco.2022.40.16_suppl.9522
Autor:
Vijay Kasturi, Marley Boyd, Frank X Liu, Ruth Kim, Charles Lance Cowey, Abhijeet Bhanegaonkar, Nicole Fulcher, Stan Krulewicz
Publikováno v:
Future oncology (London, England). 17(18)
Lay abstract Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer. Because MCC progresses quickly, many patients have a poor prognosis. Avelumab is a type of drug that helps the patient's immune system to fight cancer. Avelumab was the fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0c9bbc26601f78e3446a5019311635
https://pubmed.ncbi.nlm.nih.gov/33709776
https://pubmed.ncbi.nlm.nih.gov/33709776
Autor:
Mark R. Middleton, S. Dalle, J.-J. Grob, P.A. Ascierto, Maurice Lobo, M. Del Vecchio, Helen Gogas, Marcus O. Butler, Jeffrey S. Weber, Michael Schenker, J.M.G. Larkin, L. Del La Cruz-Merino, Charles Lance Cowey, Ivan Marquez-Rodas, Michele Maio, Ana Arance, V. de Pril, V. Chiarion-Sileni, Mario Mandalà
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 147:A78-A79
Introduction Le NIVO a demontre une amelioration de la survie sans recidive (SSR) vs l’IPI chez les patients (pts) atteints d’un melanome de stade III/IV operes dans l’etude de phase 3, CheckMate 238. Les donnees mises a jour de SSR, de survie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa1b33e86e57941d41712f0a03701c2d
https://doi.org/10.1016/j.annder.2020.09.016
https://doi.org/10.1016/j.annder.2020.09.016
Autor:
Charles Lance Cowey, Frank X Liu, M. Boyd, Stan Krulewicz, Ruth Kim, Jodi Smith, Abhijeet Bhanegaonkar, N. Fulcher
Publikováno v:
Annals of Oncology. 31:S739-S740
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ad5ccb2ee4db90b917dccec3d12a379
https://doi.org/10.1016/j.annonc.2020.08.1214
https://doi.org/10.1016/j.annonc.2020.08.1214